Navigation Links
CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer
Date:2/27/2009

re inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

Additional Information

Stockholders of CV Therapeutics are advised to read CV Therapeutics' Schedule 14D-9 statement, when it becomes available, regarding the tender offer, because it will contain important information. Stockholders may obtain a free copy of the statement at the SEC's website at www.sec.gov. Stockholders may also obtain, without charge, a copy of the statement from MacKenzie Partners, Inc., which is assisting the company, by calling 800-322-2885 toll free or by calling 212-929-5500 or by emailing cvtx@mackenziepartners.com.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the year ended December 3
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights ... colors, Valoya uses proprietary LED technology to incorporate their ... uniformity which is critical in low proximity installations. The ... throughout its lifetime which is up to four times ... "The investment cost was clearly higher when compared to ...
(Date:12/19/2014)... MILLBROOK, N.Y. , Dec. 18, 2014 Egenix, ... has been elected Chairman of the Board, to succeed ... President and CEO, but will continue as a member of ... that he has added to the company over almost twenty ... The Board of Directors has established a Search ...
(Date:12/17/2014)... Based on the revenues gained from surgical ... dominated by four major players contributing to approximately ... include GE Healthcare (U.K.), Siemens AG (Germany), Philips ... Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The ... to its strong product portfolio, which includes its ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Once ... to provide a larger packaged waste water treatment plant ... King Abdullah Economic City (KAEC). Two years ago Bioshaft ... Jeddah Gate Development, serving two residential towers with an ... is over a quarter million gallons per day and ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... have another chance to strengthen ties with Japan at ... Center. , ,Sponsored by the Japan External Trade ... an inside look into how Wisconsin biotech companies are ... traveled to Japan will talk about the difficulties and ...
... are available 24 hours a day now that a new ... , ,The Web site MusicMadeInMadison.com plays more than ... the Profits, Daedalus Burn, Infinite Helix and They Drive By ... site's goal is to help both the circulation of the ...
... and Human Services Secretary Mike Leavitt announced yesterday that ... will be formed to make recommendations for a nationwide ... , ,This news makes the Digital Healthcare Conference ... 9 at the Fluno Center in Madison, even more ...
Cached Biology Technology:Wisconsin biotechs plan Japan trade mission 2Preview: Electronic health records, tech choices explored at Digital Healthcare Conference 2Preview: Electronic health records, tech choices explored at Digital Healthcare Conference 3
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... are spiritual, according to new research from Rice University. Though ... that spirituality is a separate idea one that more ... The research will be published in the June ... in-depth interviews with 275 natural and social scientists at elite ...
... human fungal infections caused by certain strains of Aspergillus ... treatments at an alarming rate, say scientists. University of ... a new test that can not only better diagnose ... resistance to azoles the class of drugs used to ...
... at Sam Houston State University and the University of Texas ... justice system in Houston to establish protocols to determine when ... , "This is a problem-solving project that seeks to determine ... William Wells, who is leading the research project at Sam ...
Cached Biology News:More than 20 percent of atheist scientists are spiritual 2Drug-resistance fears for deadly fungal disease 2Research to target untested rape kits 2Research to target untested rape kits 3
Request Info...
...
...
... purified Formulation: 50mM Tris-HCl, pH ... 0.2mM PMSF, 1mM benzamidine, 0.1% ... PP2A1 (Protein Phosphatase 2A1) partially ... sulfate precipitation, QSepharose,amino-hexyl agarose, Superdex ...
Biology Products: